Table 1.

Classification of drugs according to their mechanism of action and diseases treated

CTLA-4 inhibitors
Ipilimumab	MelanomaPediatric melanoma
Tremelimumab	Melanoma* Mesothelioma* NSCLC
PD-1 inhibitors
Nivolumab	Melanoma NSCLC HNSCC Bladder cancer Renal cell carcinoma Hepatocellular carcinoma (HCC) Hodgkin lymphoma MSI-high, MMR-deficient metastatic colorectal cancer Cancer of the stomach, esophagus and gastro-esophageal junction*
Pembrolizumab	Melanoma NSCLC Bladder cancer HNSCC Hodgkin lymphoma Cancer of the stomach and esophagus MSI-high or MMR-deficient solid tumors of any histology Squamous cell carcinoma of the skin*
Pidilizumab	Diffuse large B-cell lymphoma (DLBCL)* Follicular lymphoma (FL)* Diffuse intrinsic pontine glioma (DIPG)* Multiple myeloma*
Cemiplimab	Squamous cell carcinoma of the skin*
PD-L1 inhibitors
Atezolizumab	Bladder cancer NSCLC
Durvalumab	NSCLC Urothelial cancer of the bladder
Avelumab	Merkel cell carcinoma (MCC) Locally advanced/metastatic urothelial carcinoma
Combined treatment with CTLA-4 and PD-1 inhibitors
Ipilimumab with nivolumab	Melanoma Renal cell carcinoma Cancer of the stomach, esophagus and gastro-esophageal junction*
Combined treatment with CTLA-4 and PD-L1 inhibitors
Durvalumab with tremelimumab	Lung cancer (small cell lung cancer, NSCLC) Bladder cancer* HCC* Cancer of the head and neck area*

*Drugs undergoing clinical trials